Galectin Therapeutics is a biotechnology company focused on developing innovative therapies for serious diseases by targeting galectin proteins, which play a crucial role in the body’s immune response and disease progression
The company is dedicated to advancing its research and product pipeline, particularly in the realms of liver disease and cancer, aiming to improve patient outcomes through novel treatments. By leveraging its expertise in galectin biology, Galectin Therapeutics seeks to create safe and effective solutions that can address unmet medical needs and enhance the quality of life for patients suffering from various conditions.
Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.
Galectin Therapeutics (NASDAQGALT) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Dow Jones gained by more than 300 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Gainers Athersys, Inc. (NASDAQATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
